ArticleFrontiers in neurology
Comprehensive analysis of m6A RNA methylation regulators and the immune microenvironment in spinal cord injury.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Spinal cord injury (SCI) is devastating neurological disorder that leads to severe physical disabilities, reduced quality of life, and a substantial socioeconomic burden. N6-methyladenosine (m6A) RNA modification has emerged as an important regulator of RNA metabolism and immune responses; however, its role in SCI remains poorly understood. Methods: Transcriptomic datasets were obtained from the Gene Expression Omnibus (GEO) to identify differentially expressed m6A regulators in SCI. Hub genes were screened using multiple machine learning algorithms and further validated in an independent dataset. Immune cell infiltration was assessed using single-sample gene set enrichment analysis (ssGSEA), and miRNA-gene-TF interaction networks were constructed using NetworkAnalyst. Single-cell RNA sequencing (scRNA-seq) data were analyzed to characterize the cellular distribution of candidate genes. Finally, the expression of candidate genes was validated in a rat SCI model using quantitative real-time PCR (qRT-PCR) and immunofluorescence staining. Results: Fourteen differentially expressed m6A regulators were identified, among which eight candidate genes were selected using machine learning approaches. FTO and YTHDC1 were further identified as hub genes through validation in an independent dataset. Immune infiltration analysis revealed significant alterations in immune cell composition in SCI, and both FTO and YTHDC1 were significantly associated with multiple immune cell subsets. Consistent with increased m6A activity in microglia and astrocytes observed in scRNA-seq analysis, Conclusion: These findings suggest that FTO and YTHDC1 may play important roles in the pathogenesis of SCI and represent potential biomarkers and therapeutic targets for further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.